与儿科白内障相关的药物:现实世界药物监督研究
Jiantong Du1, Chen Xing1, Zhiyue Zhang1
1Department of Ophthalmology, Peking University First Hospital, Beijing 100034, China.
Children (Basel, Switzerland)
|February 27, 2026
概括
儿科白内障可能与某些药物有关,包括葡萄皮质类药物和CFTR调节剂. 这项研究确定了24种具有显著药物监测信号的药物,突出显示了儿童需要仔细的眼部监测的必要性.
科学领域:
- 药物监督和药物安全研究.
- 儿科眼科和公共卫生.
背景情况:
- 儿科白内障是全球不可逆转视力丧失的主要原因.
- 识别致病原体对于预防和管理至关重要.
- 美国食品和药物管理局的不良事件报告系统 (FAERS) 提供了一个有价值的数据来源.
研究的目的:
- 使用FAERS数据识别儿科白内障的潜在药监信号.
- 分析特定药物与儿童白内障发生之间的关联.
- 为儿童白内障风险提供全面的药物安全概况.
主要方法:
- 从FAERS (2004年第一季度至2025年第三季度) 对0-17岁的个人进行真实世界的数据分析.
- 数据的标准化和多重不成比例分析的应用 (ROR,PRR,BCPNN,MGPS).
- 对药物特异性信号和白内障发病时间的评估.
主要成果:
- 在690,374份儿科报告中,发现了671份涉及232种药物的白内障病例.
- 对于24种药物,特别是葡萄糖皮质类药物和囊性纤维化转膜导电调节器 (CFTR) 调节器,发现了显著的药物监测信号.
- 双烯酸盐,伊瓦卡夫托和组合CFTR调节剂显示出高风险信号.
结论:
- 这项研究提出了与药物相关的儿科白内障的大规模药物监测概况.
- 已识别的高风险药物需要在儿科患者中进行主动的眼部监测.
- 结果支持临床决策,预防策略和药物诱导白内障的未来研究.
相关概念视频
01:19Pharmacovigilance
1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
384
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
384
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
336
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
336
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
289
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
289
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
381
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
381
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
765
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
765